Dr. Reddy's Laboratories (NSE:DRREDDY, BOM:500124) recorded a decline in its consolidated attributable profit to 12.5 billion Indian rupees in the fiscal second quarter ended Sept. 30 against 14.8 billion rupees a year ago.
Earnings per share contracted to 15.05 rupees compared with a year-ago figure of 17.76 rupees, according to a filing to the stock exchanges on Tuesday by the pharmaceutical company.
Revenue from operations in fiscal Q2 increased to 80.2 billion rupees from 68.8 billion rupees a year earlier.
Shares of the company were up over 1% in recent trade.
Price (INR): ₹1318.10, Change: ₹+15, Percent Change: +1.16%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。